Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment

A Molecular Subtype–Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010

(2018) Diego F. Munoz et al.   MEDICAL DECISION MAKING

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies

(2016) Jeanne S. Mandelblatt et al.   ANNALS OF INTERNAL MEDICINE

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes

(2016) Amy Trentham-Dietz et al.   ANNALS OF INTERNAL MEDICINE

Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality

(2014) Diego Munoz et al.   JNCI-Journal of the National Cancer Institute

Comparative Effectiveness of Digital Versus Film-Screen Mammography in Community Practice in the United States

(2013) Karla Kerlikowske   ANNALS OF INTERNAL MEDICINE

A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of BRCA1 and BRCA2 Mutation Carriers

(2012) B. M. Sigal et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Online Tool to Guide Decisions forBRCA1/2Mutation Carriers

(2012) Allison W. Kurian et al.   JOURNAL OF CLINICAL ONCOLOGY

Biologic markers determine both the risk and the timing of recurrence in breast cancer

(2011) Laura J. Esserman et al.   BREAST CANCER RESEARCH AND TREATMENT

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH